Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023)
Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023)
Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023)
Human medicines European public assessment report (EPAR): Rekovelle, follitropin delta, Anovulation, Date of authorisation: 12/12/2016, Revision: 6, Status: Authorised
Dacarbazine : List of nationally authorised medicinal products - PSUSA/00000919/202302
Human medicines European public assessment report (EPAR): Adynovi, rurioctocog alfa pegol, Hemophilia A, Date of authorisation: 08/01/2018, Revision: 10, Status: Authorised
Guidance on handling scientific committee/other (scientific) expert group member’s declared intention to become an employee in a pharmaceutical company, a medical device company or in the biotechnology sector
Clinical Trials Information System (CTIS): Walk-in clinic - September 2023, Online, 16:00 - 17:00 Amsterdam time (CEST), from 20/09/2023 to 20/09/2023
Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human;Immunization;Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 13, Status: Authorised
Clinical Trials Information System (CTIS) bitesize talk: How to submit a transitional trial in CTIS, Online, 15:30 - 17:00 Amsterdam time (CEST), from 21/06/2023 to 21/06/2023
Stakeholder participation in information management
Nulojix (belatacept) supply shortage